Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines.

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients' lives could be significantly ...

Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics (NASDAQ: SMMT).

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (NASDAQ: ...

Pembrolizumab (Keytruda, Merck Sharp & Dohme) is indicated for 'the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and ...

MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has ...

Around a quarter of untreated lung cancer patients in England are to get access to Merck, Sharp and Dohme’s Keytruda, a decision which is a major market breakthrough for the company. However ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...

4Q23 results included charges related to the Daiichi Sankyo collaboration .